Hernán Carol - Concepedia

Author

Hernán Carol

St. Jude Children's Research Hospital

Also Known As

H Carol, H. Carol, HERNAN CAROL, HERNÁN CAROL, Hernan Carol, Hernán CAROL, Hernán Carol

183

Publications

4.4K

Citations

H-Index

Concepts

All Affiliations

St. Jude Children's Research Hospital Children's Cancer Institute Australia Center for Cancer Research Children's Hospital of Philadelphia University of Pennsylvania

About

Hernán Carol is an author at St. Jude Children's Research Hospital specializing in medicine, immunology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	16	599
2	Allergy	3	3	100
3	Education	1	1	29
4	Health Sciences	1	1	21
5	Natural Sciences	1	1	10

Hernán Carol

Publications

4.2K

Citations

H-Index

Page 1

	Year	Citations
The pediatric preclinical testing program: Description of models and early testing results Peter J. Houghton, Christopher L. Morton, Chandra L. Tucker, Pediatric Blood & Cancer	2006	482
Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP) John M. Maris, Christopher L. Morton, Richard Görlick, Pediatric Blood & Cancer	2010	230
Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF‐1 receptor by the pediatric preclinical testing program E. Anders Kolb, Richard Görlick, Peter J. Houghton, Pediatric Blood & Cancer	2008	175
Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia Seong Lin Khaw, Santi Suryani, Kathryn Evans, Blood	2016	170
Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Pediatric Blood & Cancer	2007	158
Initial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program Richard B. Lock, Hernán Carol, Peter J. Houghton, Pediatric Blood & Cancer	2007	121
Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104 Juliana Benito, Yuexi Shi, Barbara Szymanska, PLoS ONE ImmunologyBiological MicroenvironmentsPharmacotherapyImmunotherapyHuman Leukemia	2011	120
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Pediatric Blood & Cancer	2007	120
Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program Malcolm A. Smith, C. Patrick Reynolds, Min H. Kang, Clinical Cancer Research	2014	115
A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921) Yaël P. Mossé, Elizabeth Fox, David T. Teachey, Clinical Cancer Research	2019	114

Page 1